“SAFETY CONCERNS” HALT ANOTHER COVID DRUG TRIAL
With media attention focused on the COVID-19 “vaccine unicorn”, several alternative therapeutics currently in trial are getting little attention. Monoclonal antibody cocktails, touted by President Trump, claim to give COVID patients a boost of synthetic antibodies to help fight against the virus. Sounds great, but is there a catch? Eli Lilly has put their late-stage trial on hold due to a safety concern, leaving the public in the dark as to why.
POSTED: October 20, 2020